. Author manuscript; available in PMC: 2020 Sep 28.

Published in final edited form as: Lancet Child Adolesc Health. 2019 May 31;3(8):578–584. doi: 10.1016/S2352-4642(19)30115-4

Table 4:

Ongoing trials to prevent cisplatin-induced ototoxicity

	Trial description	Intervention	Planned sample size	Population	Sponsor
NCT03480971	Placebo-controlled, double blind, phase 2	Tempol piperidine nitroxide	120	Adults with head and neck cancer	Matrix Biomed
NCT01451853	Placebo-controlled, double blind, phase 2	SPI-1005 (ebselen)	80	Adults with head and neck or small cell lung cancer	Sound Pharmaceuticals
NCT02094625	Single-arm dose finding	N-acetylcysteine	60	Children with cancer	Children’s Hospital Los Angeles